Healthcare Industry News: Glaucoma
News Release - December 7, 2011
Icon Appoints Murahashi Vice President, Clinical DevelopmentSUNNYVALE, Calif. , Dec. 7, 2011 -- (Healthcare Sales & Marketing Network) -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals, today announced that Wendy Yee Murahashi , M.D. has joined the management team of IBI as Vice-President, Clinical Development. Dr. Murahashi will lead Icon Bioscience's clinical development programs based on IBI's proprietary Verisome® drug delivery technology.
"As we near the completion of our pivotal Phase 2/3 trial evaluating IBI-10090 for the treatment of inflammation in patients undergoing cataract surgery, Wendy brings to IBI relevant clinical experience that will provide immediate value to IBI," said William S. White , Chief Executive Officer of Icon Bioscience, Inc. "She will also be a tremendous asset to IBI as we prepare in 2012 to initiate our clinical programs into new areas, including uveitis and Glaucoma."
"IBI's versatile Verisome technology is poised to provide a new approach for multiple applications within the ophthalmic market," said Wendy Murahashi , M.D. "By allowing physicians the flexibility to tailor the duration of effect, it allows for personalized patient treatment while decreasing injection frequency. I look forward to working with Icon to undertake the activities necessary to execute our clinical strategy."
Prior to joining Icon Bioscience, Dr. Murahashi was a Medical Director at Genentech/Roche, Inc. where she directly responsible for clinical activities for LUCENTIS®. While in general ophthalmology private practice, she previously served as Clinical Instructor at the Portland VA Hospital/Casey Eye Institute. Dr. Murahashi received her M.D. from Loyola University Chicago , and completed her ophthalmology residency at the University of Missouri, Columbia , and subspecialty vitreoretinal fellowship training at the Retina Institute of Hawaii . She earned her B.S at University of California , Berkeley.
About the Verisome® Drug Delivery Technology
The Verisome® drug delivery technology was invented by the Founder of Icon Bioscience, Inc., Vernon G. Wong , MD. The technology encompasses over 20 related, but distinct, novel and proprietary drug delivery systems. Highly versatile, it is capable of incorporating a broad range of active agents including small molecules, proteins and monoclonal antibodies and deliver drugs in a controlled release manner for up to a year with a single injection.
About Icon Bioscience, Inc.
Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome® drug delivery platform technology. IBI is developing a broad portfolio of clinically superior specialty pharmaceuticals targeting all major ophthalmic indications including macular edema, Glaucoma, age-related macular degeneration and cataract surgery. IBI has also entered into agreements with multiple international pharmaceutical companies interested in the use of the Verisome® technology for their own ophthalmic products. For more information, please refer to www.iconbioscience.com.
Source: Icon Bioscience
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.